CEOP-R regimen: Difference between revisions
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to an immunochemotherapy regimen consisting of [[cyclophosphamide]], [[ | {{PAGENAME}} refers to an immunochemotherapy regimen consisting of [[cyclophosphamide]], [[epirubicin]], [[vincristine|vincristine (Oncovin)]], [[prednisone]] and [[rituximab]] used to treat both indolent and aggressive forms of [[Diffuse large B-cell lymphoma]].<ref name="pmid24258714">{{cite journal| author=Li Y, Yimamu M, Wang X, Zhang X, Mao M, Fu L et al.| title=Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression. | journal=Int J Hematol | year= 2014 | volume= 99 | issue= 1 | pages= 79-86 | pmid=24258714 | doi=10.1007/s12185-013-1472-z | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24258714 }} </ref> | ||
==Regimen== | ==Regimen== | ||
Revision as of 13:26, 11 March 2015
|
WikiDoc Resources for CEOP-R regimen |
|
Articles |
|---|
|
Most recent articles on CEOP-R regimen Most cited articles on CEOP-R regimen |
|
Media |
|
Powerpoint slides on CEOP-R regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on CEOP-R regimen at Clinical Trials.gov Trial results on CEOP-R regimen Clinical Trials on CEOP-R regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on CEOP-R regimen NICE Guidance on CEOP-R regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on CEOP-R regimen Discussion groups on CEOP-R regimen Patient Handouts on CEOP-R regimen Directions to Hospitals Treating CEOP-R regimen Risk calculators and risk factors for CEOP-R regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for CEOP-R regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: CEOP Regimen; Cyclophosphamide/Epirubicin/Vincristine/Prednisone
Overview
CEOP-R regimen refers to an immunochemotherapy regimen consisting of cyclophosphamide, epirubicin, vincristine (Oncovin), prednisone and rituximab used to treat both indolent and aggressive forms of Diffuse large B-cell lymphoma.[1]
Regimen
Indications
References
- ↑ 1.0 1.1 Li Y, Yimamu M, Wang X, Zhang X, Mao M, Fu L; et al. (2014). "Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression". Int J Hematol. 99 (1): 79–86. doi:10.1007/s12185-013-1472-z. PMID 24258714.